Market closedNon-fractional

Nkarta/NKTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Nkarta

Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.

Ticker

NKTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

South San Francisco, United States

Employees

150

Nkarta Metrics

BasicAdvanced
$377M
Market cap
-
P/E ratio
-$2.35
EPS
0.89
Beta
-
Dividend rate
$377M
0.89
19.955
19.766
18.405
18.405
-15.07%
-28.33%
0.8
0.8
-2.254
-5.72%
-17.27%

What the Analysts think about Nkarta

Analyst Ratings

Majority rating from 9 analysts.
Buy

Nkarta Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$30M
6.50%
Profit margin
0.00%
NaN%

Nkarta Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 3.84%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.68
-$0.52
-$0.57
-$0.58
-
Expected
-$0.68
-$0.67
-$0.59
-$0.56
-$0.44
Surprise
0.00%
-22.82%
-3.59%
3.84%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Nkarta stock?

Nkarta (NKTX) has a market cap of $377M as of July 06, 2024.

What is the P/E ratio for Nkarta stock?

The price to earnings (P/E) ratio for Nkarta (NKTX) stock is 0 as of July 06, 2024.

Does Nkarta stock pay dividends?

No, Nkarta (NKTX) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Nkarta dividend payment date?

Nkarta (NKTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Nkarta?

Nkarta (NKTX) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Nkarta stock

Buy or sell Nkarta stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing